Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.

Authors:
Pagan FL; Hebron ML; Wilmarth B; Torres-Yaghi Y; Lawler A and 13 more

Journal:
JAMA Neurol

Publication Year: 2020

DOI:
10.1001/jamaneurol.2019.4200

PMCID:
PMC6990742

PMID:
31841599

View on PubMed View on PMC View Publisher
Journal Information

Full Title: JAMA Neurol

Abbreviation: JAMA Neurol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomiz…
Zhang X; Zhong W; Xue R and 38 more (2024) - Transparency Score: 3/6
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
Cross AH; Gelfand JM; Thebault S and 30 more (2024) - Transparency Score: 1/6
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
Benallegue N; Rollot F; Wiertlewski S and 28 more (2024) - Transparency Score: 2/6
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk o…
Yan S; Jiang C; Janzen A and 8 more (2024) - Transparency Score: 1/6
Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized…
Fu Y; Wang A; Tang R and 25 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Evidence found in paper:

"Trial Registration ClinicalTrials.gov identifier: NCT02954978"

Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025